Literature DB >> 31016561

Going Third Class: Treatment of Steroid-Dependent Ulcerative Colitis.

Helen Lee1, Yecheskel Schneider1, Gary R Lichtenstein2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31016561     DOI： 10.1007/s10620-019-05610-w

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  13 in total

1.  Long-term outcome of ulcerative colitis in patients who achieve clinical remission with a first course of corticosteroids.

Authors:  Esther Garcia-Planella; Míriam Mañosa; Manuel Van Domselaar; Jordi Gordillo; Yamile Zabana; Eduard Cabré; Antonio López San Román; Eugeni Domènech
Journal:  Dig Liver Dis       Date:  2011-11-11       Impact factor: 4.088

2.  European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis.

Authors:  E F Stange; S P L Travis; S Vermeire; W Reinisch; K Geboes; A Barakauskiene; R Feakins; J F Fléjou; H Herfarth; D W Hommes; L Kupcinskas; P L Lakatos; G J Mantzaris; S Schreiber; V Villanacci; B F Warren
Journal:  J Crohns Colitis       Date:  2008-01-18       Impact factor: 9.071

3.  Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel Diseases.

Authors:  Erwin Dreesen; Bram Verstockt; Sumin Bian; Magali de Bruyn; Griet Compernolle; Sophie Tops; Maja Noman; Gert Van Assche; Marc Ferrante; Ann Gils; Séverine Vermeire
Journal:  Clin Gastroenterol Hepatol       Date:  2018-04-25       Impact factor: 11.382

Review 4.  Ulcerative Colitis Care Pathway.

Authors:  Themistocles Dassopoulos; Russell D Cohen; Ellen J Scherl; Ronald M Schwartz; Lawrence Kosinski; Miguel D Regueiro
Journal:  Gastroenterology       Date:  2015-05-27       Impact factor: 22.682

Review 5.  American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease.

Authors:  Joseph D Feuerstein; Geoffrey C Nguyen; Sonia S Kupfer; Yngve Falck-Ytter; Siddharth Singh
Journal:  Gastroenterology       Date:  2017-08-03       Impact factor: 22.682

6.  Frequency of glucocorticoid resistance and dependency in Crohn's disease.

Authors:  P Munkholm; E Langholz; M Davidsen; V Binder
Journal:  Gut       Date:  1994-03       Impact factor: 23.059

7.  A prospective cohort study to assess the relevance of vedolizumab drug level monitoring in IBD patients.

Authors:  Hermann Schulze; Philip Esters; Franz Hartmann; Juergen Stein; Christina Christ; Michael Zorn; Axel Dignass
Journal:  Scand J Gastroenterol       Date:  2018-03-21       Impact factor: 2.423

8.  The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort.

Authors:  G-T Ho; P Chiam; H Drummond; J Loane; I D R Arnott; J Satsangi
Journal:  Aliment Pharmacol Ther       Date:  2006-07-15       Impact factor: 8.171

9.  Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study.

Authors:  W Yacoub; N Williet; L Pouillon; T Di-Bernado; M De Carvalho Bittencourt; S Nancey; A Lopez; S Paul; C Zallot; X Roblin; L Peyrin-Biroulet
Journal:  Aliment Pharmacol Ther       Date:  2018-01-31       Impact factor: 8.171

Review 10.  Surgical management of ulcerative colitis in the era of biologicals.

Authors:  Bikash Devaraj; Andreas M Kaiser
Journal:  Inflamm Bowel Dis       Date:  2015-01       Impact factor: 5.325
View more
  1 in total

1.  Activated inducible co-stimulator-positive programmed cell death 1-positive follicular helper T cells indicate disease activity and severity in ulcerative colitis patients.

Authors:  Y Long; X Zhao; Chang Liu; C Xia; Chen Liu
Journal:  Clin Exp Immunol       Date:  2020-07-28       Impact factor: 4.330
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.